共 118 条
[1]
Schreiber S(2023)Major adverse cardiovascular events by baseline cardiovascular risk in patients with ulcerative colitis treated with tofacitinib: data from the OCTAVE clinical programme J Crohns Colitis 17 1761-1770
[2]
Rubin DT(2023)Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis RMD Open 9 e002735-27
[3]
Ng SC(2023)European Crohn’s and colitis guidelines on sexuality, fertility, pregnancy, and lactation J Crohns Colitis 17 1-765
[4]
Peyrin-Biroulet L(2022)National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs) Wien Klin Wochenschr 134 751-895
[5]
Danese S(2020)Increased discontinuation rates of anti-TNF therapy in elderly inflammatory bowel disease patients J Crohns Colitis 14 888-1085
[6]
Modesto I(2020)Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study United Eur Gastroenterol J 8 1076-304
[7]
Guo X(2022)Oral surveillance and JAK inhibitor safety: the theory of relativity Nat Rev Rheumatol 18 301-3147
[8]
Su C(2022)Real-world effectiveness and safety of Ustekinumab in elderly Crohn’s disease patients Dig Dis Sci 67 3138-undefined
[9]
Kwok KK(2022)Safety of ustekinumab and vedolizumab during pregnancy—pregnancy, neonatal and infant outcome: a prospective multicenter study J Crohns Colitis 12 651415-undefined
[10]
Jo H(2021)Novel and Emerging Therapies for Inflammatory Bowel Disease Front Pharmacol undefined undefined-undefined